FDA-approved
Sexual & reproductive
Leuprolide
Evidence
FDA approved
Class
GnRH agonist
KEY TAKEAWAY
Leuprolide is a nine-amino-acid synthetic GnRH agonist. It is sold as Lupron Depot, Eligard and under other names. The FDA approved leuprolide (Lupron) in 1985 for advanced prostate cancer, and approved formulations now cover several other conditions.
Written by the Veylo editorial team · Updated
November 2026
What it is
GnRH agonist
Approved for
Advanced prostate cancer, endometriosis, fibroids and central precocious puberty
Key fact
The FDA approved leuprolide (Lupron) in 1985 for advanced prostate cancer, and approved formulations now cover several other conditions.
Route
Injection or implant, given monthly to every 6 months
Evidence strength
FDA approved
Leuprolide is a nine-amino-acid synthetic GnRH agonist. It is sold as Lupron Depot, Eligard and under other names.
It first stimulates and then desensitizes GnRH receptors, which lowers testosterone and estrogen.
The FDA approved leuprolide (Lupron) in 1985 for advanced prostate cancer, and approved formulations now cover several other conditions.
Advanced prostate cancer, endometriosis, fibroids and central precocious puberty.
Hot flashes, bone density loss, fatigue and sexual side effects are common. Hormone levels can briefly rise at the start of treatment.
U.S. FDA prescribing information for Leuprolide. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.